These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29869050)

  • 1. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults.
    Altawalbeh SM; Thorpe CT; Zgibor JC; Kane-Gill S; Kang Y; Thorpe JM
    J Manag Care Spec Pharm; 2018 May; 24(5):478-486. PubMed ID: 29694289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
    Ducharme FM; Lasserson TJ; Cates CJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003137. PubMed ID: 17054161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
    Ram FS; Cates CJ; Ducharme FM
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003137. PubMed ID: 15674901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
    Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
    Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
    Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
    Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.
    Greenstone IR; Ni Chroinin MN; Masse V; Danish A; Magdalinos H; Zhang X; Ducharme FM
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005533. PubMed ID: 16235409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults.
    Ni CM; Greenstone IR; Ducharme FM
    Cochrane Database Syst Rev; 2005 Apr; (2):CD005307. PubMed ID: 15846751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-inhaler combination therapy for asthma: a review of cost effectiveness.
    Akazawa M; Stempel DA
    Pharmacoeconomics; 2006; 24(10):971-88. PubMed ID: 17002480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost considerations of therapeutic options for children with asthma.
    Chuang S; Jaffe A
    Paediatr Drugs; 2012 Aug; 14(4):211-20. PubMed ID: 22642813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables.
    Navarro RP; Parasuraman B
    Manag Care Interface; 2005 Jun; 18(6):31-40. PubMed ID: 16018297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice.
    Goossens LM; Riemersma RA; Postma DS; van der Molen T; Rutten-van Mölken MP
    Adv Ther; 2009 Sep; 26(9):872-85. PubMed ID: 19768640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
    Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
    Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and resource use of mild persistent asthma patients initiated on controller therapy.
    Colice GL; Yu AP; Ivanova JI; Hsieh M; Birnbaum HG; Lage MJ; Brewster C
    J Asthma; 2008 May; 45(4):293-9. PubMed ID: 18446593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic review of medical management of persistent asthma.
    Cheng JW; Arnold RJ
    Allergy Asthma Proc; 2008; 29(2):109-22. PubMed ID: 18430307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis.
    Sobieraj DM; Weeda ER; Nguyen E; Coleman CI; White CM; Lazarus SC; Blake KV; Lang JE; Baker WL
    JAMA; 2018 Apr; 319(14):1485-1496. PubMed ID: 29554195
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.